2018
DOI: 10.1016/j.gofs.2018.10.007
|View full text |Cite
|
Sign up to set email alerts
|

Contraception hormonale et risque vasculaire. RPC Contraception CNGOF

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0
2

Year Published

2018
2018
2021
2021

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(12 citation statements)
references
References 87 publications
0
10
0
2
Order By: Relevance
“…As complicações relacionadas ao seu uso, são consideradas as maiores determinantes no perfil benefício/malefício do contraceptivo hormonal, e portanto, recomenda-se uma pesquisa de fatores de risco vasculares antes da prescrição a fim de adaptar a estratégia contraceptiva de acordo com o perfil de cada mulher (27) . Dentre as principais complicações destaca-se: o acidente vascular cerebral, o infarto do miocárdio e a TVP.…”
Section: Discussionunclassified
“…As complicações relacionadas ao seu uso, são consideradas as maiores determinantes no perfil benefício/malefício do contraceptivo hormonal, e portanto, recomenda-se uma pesquisa de fatores de risco vasculares antes da prescrição a fim de adaptar a estratégia contraceptiva de acordo com o perfil de cada mulher (27) . Dentre as principais complicações destaca-se: o acidente vascular cerebral, o infarto do miocárdio e a TVP.…”
Section: Discussionunclassified
“…La contraception estro-progestative quelle que soit sa voie d’administration ainsi que la contraception progestative intramusculaire par acétate de médroxyprogestérone augmentent le risque de maladie veineuse thromboembolique (MVTE). Les autres types de contraception progestative seule (comprimés, implant ou dispositif intra-utérin) ne modifient pas la coagulation et ne sont pas associés au risque de MVTE [10] . Le traitement hormonal de ménopause utilisant de l’estradiol par voie orale augmente ce risque alors que l’administration d’estradiol par voie transdermique associée à la progestérone naturelle est neutre [11] .…”
Section: Quelle Prévention Des éVènements Thromboemboliques Chez Les Femmes Utilisant Un Traitement Hormonal Et Ayant Le Covid-19?unclassified
“…41 Nevertheless, at 35 years of age, the risk of thrombosis in women who use contraceptives is the same as that in pregnant women. 40 In the contraceptive formula, estrogen fits as the ethologic agent for hemostatic disfunctions. According to Gialeraki et al, 42 the risk of thrombosis is double in women who take pills containing high doses of estrogen.…”
Section: Hormonal Formulations and Thrombotic Riskmentioning
confidence: 99%
“…39 Regarding progestogens, there is a global consensus that, except for medroxyprogesterone acetate deposit, there is no significant association between the isolated use of progestin and increased VTE Even in high doses of Levonogestrel or ulipristalpresent in the formulation of emergency pills, isolated, are also not associated with vascular events. 40,44 Regarding combined oral contraceptives (COC), the risk of developing VTE is much higher if compared with other isolated formulations. This risk dependent on the dose of EE together with gestodene, desogestrel, cyproterone acetate or drospirenone (3 rd and 4 th generation progestins).…”
Section: Hormonal Formulations and Thrombotic Riskmentioning
confidence: 99%